ResMed touts study demonstrating impact of CPAP on chances of living longer

September 9, 2021 By Sean Whooley

Image from ResMed

ResMed (NYSE:RMD) is touting data highlighting the use of PAP therapy and its connection to potentially living longer.

A late-breaking abstract presented at the virtual European Respiratory Society (ERS) International Congress 2021, supported by ResMed, found that using positive airway pressure (PAP) therapy as directed can significantly increase sleep apnea patients’ chances of living longer, according to a news release.

Get the full story at our sister site, MassDevice.

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.